Please login to the form below

Not currently logged in


This page shows the latest ramucirumab news and features for those working in and with pharma, biotech and healthcare.

Lilly scores FDA okay for Cyramza in liver cancer

Lilly scores FDA okay for Cyramza in liver cancer

The FDA approval is for Cyramza (ramucirumab) – a VEGF receptor 2 antagonist – as a second-line treatment after Bayer’s multikinase inhibitor Nexavar (sorafenib), often used as a first-line targeted

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...